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Identity 
Other names: NIS 
HGNC (Hugo): SLC5A5 
Location: 19p13.11 




The SLC5A5 gene was first sequenced in 1996 from rat 
and subsequently human thyroid (Dai et al., 1996; 
Smanik et al., 1996) and the exon-intron organization 
characterized in 1997 (Smanik et al., 1997). 
Description 
15 exons, spanning 23202 bp. 
Transcription 
Transcription starts at -375 relative to the ATG site. 
The minimal promoter is localized to a region of 144 
bp that includes a 90-bp stretch (-478 and -389 bp) with 
73% identity to the rat NIS proximal promoter and 
containing a TATA- and a GC-box. The region 
between -596 and -415 is essential for full promoter 
activity in human thyroid cells. A human NIS gene 5' 
far-upstream enhancer (hNUE) (-9847 to -8968) 
confers thyroid-specific and TSH-cAMP responsive 
transcription and contains an essential Pax-8 binding 
site and a cAMP response element (CRE)-like 
sequence activated by a CRE  
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modulator (CREM) (Taki et al., 2002; Fenton et al., 
2008). 
RNA: 3576 bases, open reading frame: 1929 bp. No 
splice variants are reported. 
Pseudogene 
No pseudogenes have been identified. 
Protein 
Note 
The protein encoded by the SLC5A5 gene is more 
commonly referred to in the scientific literature as the 
Sodium Iodide Symporter or NIS. 
Description 
NIS is a glycoprotein with 643 aa and predicted 
molecular weight 69k Da. It is composed of 13 
transmembrane domains, an extracellular N-terminal, a 
cytosolic C-terminal and three N-linked glycosylation 
sites at positions 225, 485 and 497. NIS is 
phosphorylated in vivo, mostly at the level of serin s. 
Expression 
NIS is highly expressed and is active in the thyroid, 
stomach, salivary glands and lactating mammary gland. 
Low levels of NIS have also been detected by 
immunohistochemistry and/or RT-PCR in other 
extrathyroidal tissues (small intestine, colon, rectum, 
pancreas, kidney, bile duct, lung, lacrimal gland, heart, 
placenta, testis, ovaries, prostate gland, adrenal gland, 
thymus and pituitary gland), but it is not clear to what 
extent it is active in these tissues. 
Localisation 
Cell membrane. NIS is located on the basolateral 
membrane of thyroid follicular cells, lactating  
mammary gland alveolar cells, salivary gland ductal 
epithelial cells and gastric mucin-secreting cells. In 
contrast, NIS is located on the apical membrane of 
placental trophoblasts and enterocytes. In the kidney, 
NIS has a diffuse cytoplasmic distribution in distal 
tubular cells, but is more prominent in the basolateral 
aspect of proximal tubular cells. 
Function 
NIS mediates the transport of iodide (I-) into cells; it 
cotransports Na+ and I- on a 2:1 basis, using the 
inwardly directed Na+ concentration gradient generated 
by the Na+-K+ ATPase to concentrate I- to 30-50 times 
the extracellular concentration. 
The major function of NIS is to concentrate I- in the 
thyroid for the synthesis of thyroid hormones 
triiodothyronine (T3) and tetraiodothyronine (T4). 
Iodine, a trace element obtained with the diet, is 
organified into the thyroid hormone precursor 
thyroglobulin by thyroid peroxidase in the presence of 
hydrogen peroxide. Thyroidal NIS is regulated by 
thyroid stimulating hormone (TSH) under control of 
the hypothalamic-pituitary axis. Low circulating levels 
of T3 and T4 stimulate the release of thyrotropin-
releasing hormone (TRH) from the hypothalamus, 
which in turn stimulates the secretion of TSH from the
anterior pituitary gland. TSH increases NIS expression 
resulting in enhanced I- uptake and thyroid hormone 
synthesis. In contrast, high levels of circulating T3 and 
T4 inhibit TSH production through a negative feedback 
loop reducing iodide uptake and thyroid hormone 
production. TSH regulates NIS transcription via a 
cAMP-dependent pathway requiring binding of 
transcription factors Pax-8 and CREM to the hNUE 
enhancer element. TSH also regulates NIS trafficking, 
promoting NIS targeting to the plasma membrane. 
 
The diagram has been drawn following UniProtKB/Swiss-Prot database prediction and maintaining approximate length proportions 
among extracellular and intracellular segments. Transmembrane segments are represented by green rectangles, N-glycosylation sites in 
yellow. 
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Mammary gland NIS drives the secretion of I- into milk 
in fulfillment of the newborn's dietary requirement for 
iodine and is induced by lactogenic hormones 
(prolactin, oxytocin). 
Placental NIS may provide the fetus with the necessary 
I- to synthesize thyroid hormones. 
NIS function in other tissues is unclear. I- secretion 
may play a role in mucosal host defense through the 
formation of reactive metabolites of iodine with 
antimicrobial activity. A role for NIS in the transport of 
thiocyanate and nitrate across mucosal barriers has also 
been proposed, again resulting in the formation of 
antimicrobial molecules. 
Homology 
NIS belongs to the SLC superfamily of solute carriers. 
The SLC5 family has 12 members to date (SLC5A1-
SLC5A12) and includes Na+-coupled cotransporters 
that rely on the Na+ electrochemical gradient to drive 
solute transport into cells. NIS (SLC5A) has the highest 
homology with SLC5A12 (48% identity) and SLC5A8 
(46% identity), both of which are thought to be 
sodium/monocarboxylate transporters and SLC5A6 
(42% identity), a sodium/multivitamin transporter. 
Mutations 
Germinal 
Germinal NIS mutations cause Iodide Transport Defect 
(ITD), a rare form of dyshormogenic congenital 
hypothyroidism with autosomal recessive inheritance 
(OMIM 274400). Twelve loss-of-function mutations 
have been reported to date: V59E, G93R, R124H, 
∆M143-Q323, Q267E, C272X, T354P, G395R, 
∆A439-P443, frame-shift 515X, Y531X, G543E.  
Mutations reduce thyroidal iodide uptake as a result of 
impaired NIS expression, maturation, trafficking or
transport activity. 
Somatic 
A loss-of-function deletion of exon 6 was identified in 
a single case of follicular thyroid adenoma (Liang et 
al., 2005). No other somatic mutations have been 




NIS-mediated uptake of radionuclides has long been 
exploited in diagnostic scintigraphic imaging (123I, 131I, 
99mTcO4
-) and radiotherapy (131I) of thyroid carcinoma 
of follicular cell origin. Compared to other cancers, the 
prevalence of thyroid cancer is relatively low and its 
prognosis after surgery and radioiodine therapy is 
mostly favorable. However, radioiodine uptake is 
frequently decreased in differentiated thyroid 
carcinoma (papillary and follicular) and is complete y 
absent in 20% of differentiated carcinomas and most 
anaplastic thyroid carcinomas. Furthermore, the 
recurrence rate of thyroid cancer is high (10-30% for 
papillary thyroid carcinoma) and only one third of 
patients with distant metastases respond to 131I therapy 
with complete remission. 
NIS expression in thyroid cancer is controversial with 
reports of under-expression as well as over-expression 
(Arturi et al., 1998; Saito et al., 1998; Venkataraman et 
al., 1999; Lazar et al., 1999; Castro et al., 2001; Dohan 
et al., 2001; Ward et al., 2003; Trouttet-Masson et al., 
2004).  
 
Localisation of NIS mutations identified in iodide transport defect (ITD) (in red) and thyroid follicular adenoma (in blue). 
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Low NIS expression identifies aggressive thyroid 
tumors and correlates with reduced radioiodine uptake 
and tumor dedifferentiation. Loss of NIS expression 
may be associated with hypermethylation of the NIS 
gene promoter, or may be secondary to reduced 
expression of nuclear transcription factors. When over-
expressed, NIS is mostly intracellular suggesting 
defective targeting of the protein to the plasma 
membrane in these cases. Hypofunctioning thyroid 
tumors express low levels of non-glycosylated NIS 
suggesting that protein maturation may also be 
impaired. 
Several pharmacological approaches are being tested 
for their ability to promote cellular re-differentia on, 
increase endogenous NIS expression and restore iodide 
transport in thyroid carcinoma cell lines and in patients. 
Agents include retinoic acid, demethylating agents, 
histone deacetylase inhibitors and reverse transcriptase 
inhibitors (Schmutzler et al., 1997; Venkataraman et 
al., 1999; Zarnegar et al., 2002; Fortunati et al., 2004; 
Landriscina et al., 2005). The effectiveness of these 
agents, however, is variable and their clinical utility has 
yet to be proven. 
Oncogenesis 
Although no somatic NIS mutations have been 
identified in thyroid carcinoma, alterations in other 
genes or gene products may be associated with NIS 
impairment. 
BRAF: Papillary thyroid carcinomas (PTC) harboring 
the BRAF V600E mutation have reduced NIS 
expression and impaired targeting to the plasma 
membrane, which correlates with reduced radioiodine 
uptake and high risk of recurrence (Riesco-Eizagirre et 
al., 2006). BRAF V600E-positive PTC also have 
reduced expression of other thyroid-specific genes such 
as thyroperoxidase and thyroglobulin, suggesting that
impaired NIS expression may be part of an early 
dedifferentiation process present at the molecular level 
in BRAF V600E-mutated PTC (Durante et al., 2007; 
Romei et al., 2008). 
RET/PTC: Expression of RET/PTC rearrangements 
reduces radioiodide uptake and NIS expression in 
thyroid cells in vitro and transgenic mice (Cho et al.,
1999; Knauf et al., 2003). No change in NIS 
expression, however, was detected in papillary thyroid 
carcinoma with RET/PTC rearrangements (Romei et 
al., 2008). 
PTTG: Differentiated thyroid cancer over-expresses 
pituitary tumor transforming gene (PTTG), a proto-
oncogene involved in the control of sister chromatid 
separation. PTTG overexpression correlates with 
reduced radioiodine uptake and is a prognostic factor 
for persistent disease (Saez et al., 2006).  
PTTG downregulates NIS expression and I- uptake in 
vitro, possibly by repressing the binding of 
transcriptional regulators to the hNUE upstream 
enhancer (Boelaert et al., 2007). 
Breast cancer 
Disease 
NIS is up-regulated in breast cancer and attention has 
recently focused on the potential application of 
radioiodine in the diagnosis and therapy of breast 
cancer. Several studies have detected NIS 
immunohistochemically in 30-90% of primary and 
metastatic breast carcinomas, with variable degrees of 
intracellular and plasma membrane staining (Tazebay 
et al, 2000; Wapnir et al, 2003; Wapnir et al., 2004; 
Beyer et al., 2008; Renier et al., 2009). Estimates of 
NIS expression in breast cancer, however, may be 
overestimated due to non-specific binding of some anti-
NIS antibodies resulting in a diffuse intracellular 
staining. One study failed to detect significant NIS 
immunostaining in 30 cases of primary breast cancer 
(Peyrottes et al., 2009). In vivo scintigraphic imaging 
detected 123I or 99mTcO4 uptake in up to 25% of NIS-
expressing breast tumors, suggesting that the 
expression of functional NIS in breast cancer is low 
(Moon et al., 2001; Wapnir et al., 2004). Current 
research is aimed at identifying strategies that increase 
the expression and membrane targeting of NIS in breast 
cancer, in order to improve the efficiency of NIS-
mediated radionuclide uptake. 
Cholangiocarcinoma (CCA) 
Disease 
NIS is up-regulated in CCA and is localized to the 
plasma membrane and/or cytoplasm of bile duct 
epithelial cholangiocytes. In the diethylnitrosamine rat 
model of liver cancer, NIS is expressed at the 
preneoplastic stages of liver carcinogenesis and enabl s 
tumor suppression after 131I radiotherapy (Liu et al., 
2007). Radioiodide therapy may therefore represent a 
novel strategy for the treatment of CCA. 
Gastric cancer 
Disease 
NIS expression, normally present in the gastric mucosa, 
is markedly decreased or absent in gastric cancer 
(Altorjay et al., 2007) and distinguishes malignant from 
benign gastric lesions (Farnedi et al., 2009). 
Various carcinomas 
Note 
Targeted NIS gene therapy is being evaluated as a 
potential diagnostic and therapeutic option for various 
cancers, enabling tumor cells to accumulate NIS-
transported radionuclides. Preclinical studies 
demonstrate NIS expression, radioiodide uptake and 
tumor cell death in vitro and in vivo following targeted 
adenoviral NIS gene transfer to tumor cells. A phase I 
clinical trial is ongoing to study the efficacy and safety 
of NIS gene therapy and radioactive iodine for the 
treatment of prostate cancer (NCT00788307, 
www.clinicaltrials.gov). 
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Disease 
Carcinomas of the prostate, cervix, breast, head and 




Benign nonfunctioning thyroid adenomas are 
characterized by reduced radioiodine uptake due to 
reduced NIS expression or defective targeting of NIS to 
the plasma membrane (Tonacchera et al., 2002). A 
loss-of-function deletion of exon 6 of the NIS gene was 
identified in a single case of follicular thyroid aenoma 
(Liang et al., 2005). Hyperfunctioning toxic adenomas 
harbor activating mutations of the TSH receptor andre 
characterized by increased NIS expression with corre t 
plasma membrane localization (Lazar et al., 1999). 
Congenital hypothyroidism 
Disease 
Germinal NIS mutations causing iodide transport defect 
(ITD) are a rare cause of dyshormogenic congenital 
hypothyroidism (OMIM 274400). To date, 12 
mutations have been reported (V59E, G93R, R124H, 
∆M143-Q323, Q267E, C272X, T354P, G395R, 
∆A439-P443, frame-shift 515X, Y531X, G543E) 
leading to reduced or absent thyroidal radioiodine 
uptake, low iodide saliva: plasma ratios and a variable 
degree of hypothyroidism and goiter. 
Prognosis 
Goitre, severe neuro-developmental impairment and 
infertility if not treated. Hypothyroidism treated with 
T4-replacement therapy and I
- supplementation. 
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